Adjuvant tislelizumab plus lenvatinib

Phase 3Small molecule

Adjuvant tislelizumab plus lenvatinib is one of 13 small molecule programs targeting Recurrence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RecurrenceRecruiting

RecurrencePhase 3

Recruiting

Competition

Competitive Landscape

14 competitors in Recurrence

#DrugCompanyPhaseTrials

Aromasin

Pfizer

Phase 2

2 2

Trodelvy

Gilead

Phase 2

1 3

Tecentriq

Roche

Phase 2

1 4

Erleada

Johnson & Johnson

Phase 2

1 5

Kisqali

Novartis

Phase 2

1 6

Femara

Novartis

Phase 2

1 7

Nolvadex

AstraZeneca

Phase 2

1 8

Arimidex

IIstituto Clinico Humanitas

Phase 2

1 9

Faslodex

FFresenius Kabi USA, LLC

Phase 2

1 10

Androgen Deprivation Therapy

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Recurrence

NCT07417397

Clinical

Trials by Indication[1]

Recurrence1 trial

Adjuvant TACE in HCC With High-risk Recurrence Factors

Recruiting·GGuangxi Medical University·Phase 3·NCT07417397·442 enrolled

Tislelizumab1 trial

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Unknown status·GGuangxi Medical University·Phase 3·NCT05910970·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Adjuvant tislelizumab plus lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adjuvant tislelizumab plus lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adjuvant tislelizumab plus lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangxi Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGuangxi Medical University

Adjuvant tislelizumab plus lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Recurrence1 trial

Tislelizumab1 trial

References

Drug Info

Quick Facts

Related News